Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Medical Research Journal
MENU
Shortcuts Submit an article Author Guidelines Reviewers 2023 Focus and Scope

open access

Vol 4, No 3 (2019)
Original article
Published online: 2019-09-10
View PDF Download PDF file
Get Citation

Human Epidermal Growth Factor-2 Receptor [HER2] Status in Patients Aged 70 years or more with Operable Early Breast Cancer — Multicentre Based Study with Review of 150 Cases

Abdalla Saad Abdalla Al-Zawi1, Mohammed Omer2, Elizabeth Tan3, Beata Adamczyk4, Jessica English5, Mohamed Elamass3, Soad Eldruki6
DOI: 10.5603/MRJ.a2019.0031
·
Medical Research Journal 2019;4(3):157-162.
Affiliations
  1. Breast Unit, Basildon & Thurrock University Hospital, Nether Mayne, SS16 5NL Basildon, United Kingdom
  2. Department of Histopathology, Addenbrooke's Hospital, Cambridge, United Kingdom
  3. Departmet of Surgery, Basildon & Thurrock University Hospital, Nethermane, SS16 5NL Basildon, ESSEX, United Kingdom
  4. Greater Poland Cancer Centre, Poznan, Poland
  5. Basildon & Thurrock University Hospital, Nethermayne, Basildon, Essex, United Kingdom
  6. Department of pathomorphology, Benghazi Medical Centre, Benghazi, Libyan Arab Jamahiriya

open access

Vol 4, No 3 (2019)
ORIGINAL ARTICLES
Published online: 2019-09-10

Abstract

Background: Breast cancer is the most common invasive cancer in females but often has more favourable
tumour biology in the older age group. More than 30% of those diagnosed with breast cancer worldwide are
aged ≥ 65. Some report this percentage to be even higher, reaching up to more than 50% in developed
countries that have a longer overall life expectancy. Within this group, hormone receptor-positive and human epidermal growth factor-2 (HER-2) negative are the most favourable tumour biological patterns. In contrast, the triple-negative breast cancer group has the worst prognosis. Invasive breast cancers in younger age groups have a more poorly differentiated histological grade, more hormone receptor-negative status, a remarkable extent of lympho-vascular invasion and a greater expression/amplification of HER-2 than older age groups. HER-2 receptor is amplified and over-expressed in about 20–30% of invasive
breast cancers within all age groups. To analyse the status of HER-2 receptors early invasive breast cancer in relation to the histological subtype in the older age group.
Methods: The study group includes 150 patients with early breast cancer . The patho-morphological data and immune-histochemistry results of invasive cancer have been analysed, this included histology subtype,
grade, oestrogen/progesterone receptor status as well as HER-2 expression.
Results: HER-2 expression was only seen in 17% of cases, it was seen mainly in Grade 3 cancers (9%), followed by Grade 2 (6%), with Grade 1 cancer accounting for only 1% of the study group.
Conclusions: Patients with breast cancer aged ≥ 70 are seen to have less aggressive biology and expression
of HER-2 receptors.

Abstract

Background: Breast cancer is the most common invasive cancer in females but often has more favourable
tumour biology in the older age group. More than 30% of those diagnosed with breast cancer worldwide are
aged ≥ 65. Some report this percentage to be even higher, reaching up to more than 50% in developed
countries that have a longer overall life expectancy. Within this group, hormone receptor-positive and human epidermal growth factor-2 (HER-2) negative are the most favourable tumour biological patterns. In contrast, the triple-negative breast cancer group has the worst prognosis. Invasive breast cancers in younger age groups have a more poorly differentiated histological grade, more hormone receptor-negative status, a remarkable extent of lympho-vascular invasion and a greater expression/amplification of HER-2 than older age groups. HER-2 receptor is amplified and over-expressed in about 20–30% of invasive
breast cancers within all age groups. To analyse the status of HER-2 receptors early invasive breast cancer in relation to the histological subtype in the older age group.
Methods: The study group includes 150 patients with early breast cancer . The patho-morphological data and immune-histochemistry results of invasive cancer have been analysed, this included histology subtype,
grade, oestrogen/progesterone receptor status as well as HER-2 expression.
Results: HER-2 expression was only seen in 17% of cases, it was seen mainly in Grade 3 cancers (9%), followed by Grade 2 (6%), with Grade 1 cancer accounting for only 1% of the study group.
Conclusions: Patients with breast cancer aged ≥ 70 are seen to have less aggressive biology and expression
of HER-2 receptors.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

breast cancer, HER-2 receptor, trastuzumab

About this article
Title

Human Epidermal Growth Factor-2 Receptor [HER2] Status in Patients Aged 70 years or more with Operable Early Breast Cancer — Multicentre Based Study with Review of 150 Cases

Journal

Medical Research Journal

Issue

Vol 4, No 3 (2019)

Article type

Original article

Pages

157-162

Published online

2019-09-10

Page views

516

Article views/downloads

750

DOI

10.5603/MRJ.a2019.0031

Bibliographic record

Medical Research Journal 2019;4(3):157-162.

Keywords

breast cancer
HER-2 receptor
trastuzumab

Authors

Abdalla Saad Abdalla Al-Zawi
Mohammed Omer
Elizabeth Tan
Beata Adamczyk
Jessica English
Mohamed Elamass
Soad Eldruki

References (22)
  1. DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014; 64(1): 52–62.
    CrossRefPubMed
  2. National Cancer Institute: Breast cancer risk in American women. http://www.cancer.gov/cancertopics/types/breast/risk-fact-sheet (19.11.2017).
  3. Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol. 2001; 12 Suppl 1: S35–S41.
    CrossRefPubMed
  4. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001; 12 Suppl 1: S3–S8.
    CrossRefPubMed
  5. Orucevic A, Curzon M, Curzon C, et al. Breast Cancer in Elderly Caucasian Women-An Institution-Based Study of Correlation between Breast Cancer Prognostic Markers, TNM Stage, and Overall Survival. Cancers (Basel). 2015; 7(3): 1472–1483.
    CrossRefPubMed
  6. Aapro M, Wildiers H. Triple-negative breast cancer in the older population. Ann Oncol. 2012; 23 Suppl 6: vi52–vi55.
    CrossRefPubMed
  7. Daidone MG, Coradini D, Martelli G, et al. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol. 2003; 45(3): 313–325.
    PubMed
  8. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000; 92(7): 550–556.
    CrossRefPubMed
  9. Molino A, Giovannini M, Auriemma A, et al. Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer. Crit Rev Oncol Hematol. 2006; 59(3): 226–233.
    CrossRefPubMed
  10. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984; 2(10): 1102–1109.
    CrossRefPubMed
  11. Durbecq V, Ameye L, Veys I, et al. A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics. Crit Rev Oncol Hematol. 2008; 67(1): 80–92.
    CrossRefPubMed
  12. Freedman RA, Muss HB. Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient. J Geriatr Oncol. 2014; 5(1): 2–7.
    CrossRefPubMed
  13. Lodi M, Scheer L, Reix N, et al. Breast cancer in elderly women and altered clinico-pathological characteristics: a systematic review. Breast Cancer Res Treat. 2017; 166(3): 657–668.
    CrossRefPubMed
  14. Slamon D, Eiermann W, Robert N, et al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14): 1273–1283.
    CrossRefPubMed
  15. Romond E, Perez E, Bryant J, et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. N Engl J Med. 2005; 353(16): 1673–1684.
    CrossRef
  16. Leyland-Jones B, Arnold A, Gelmon K, et al. Pharmacologic insights into the future of trastuzumab. Ann Oncol. 2001; 12 Suppl 1: S43–S47.
    CrossRefPubMed
  17. Baselga J. Phase I and II clinical trials of trastuzumab. Annals of Oncology. 2001; 12(suppl 1): S49–S55.
    CrossRef
  18. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014; 32(33): 3744–3752.
    CrossRefPubMed
  19. Muss HB. Adjuvant chemotherapy in older women with breast cancer: who and what? J Clin Oncol. 2014; 32(19): 1996–2000.
    CrossRefPubMed
  20. Dall P, Lenzen G, Göhler T, et al. Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany. J Geriatr Oncol. 2015; 6(6): 462–469.
    CrossRefPubMed
  21. Denegri A, Moccetti T, Moccetti M, et al. Cardiac toxicity of trastuzumab in elderly patients with breast cancer. J Geriatr Cardiol. 2016; 13(4): 355–363.
    CrossRefPubMed
  22. Sun J, Chia S. Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly. Br J Cancer. 2017; 116(1): 4–9.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl